In this mulitcenter, observational, prospective study of stage 5 CKD patients on dialysis, the use of phosphate-binding agents was shown to lower all-cause and cardiovascular mortality by 29% and 22% respectively. All agents proved to be beneficial except aluminum salts. There interesting findings need to be confirmed in randomized clinical trials.
- Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis
- High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients
- A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis